Fall Frequency, Risk Factors, and Outcomes in Parkinson's Disease: A Cross-Sectional Analysis

Joaquin A. Vizcarra, MD*;[1,2] Kat Hefter, JD, MSE*;[3] David-Erick Lafontant, MS;[4] Michael Tran Duong, MD, PhD;[5] Ashkan Ertefaie, PhD;[6] Brian Litt, MD;[1,2] Dani S. Bassett, PhD;[3] Andrew Siderowf, MD, MSCE[1] and The Parkinson's Progression Markers Initiative

1. Department of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
2. Center for Neuroengineering and Therapeutics, University of Pennsylvania, Philadelphia, PA 19104, USA
3. Department of Bioengineering, University of Pennsylvania School of Engineering and Applied Sciences, Philadelphia, PA, USA
4. Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, IA, USA
5. Department of Radiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
6. Department of Biostatistics, Epidemiology & Informatics, University of Pennsylvania, Philadelphia, PA, USA

*These two authors contributed equally to this work

Keywords: Parkinson, fall, NSD-ISS, risk factors

Running title: Frequency, outcomes, and correlates of falling in PD

Abstract word count: 350

Manuscript word count: 4387

Figures: 2

Tables: 3

Supplementary material: 11 (6 eTables, 5 eFigures, PPMI author list)

Corresponding Author:

Joaquin A. Vizcarra, MD

Department of Neurology, University of Pennsylvania Perelman School of Medicine

330 S 9th St, Philadelphia, PA, USA 19107

(215) 829-6500

vizcarj@pennmedicine.upenn.edu

Financial Disclosure/Conflict of Interest: none

Funding: This work was supported by the National Institute of Health (1T32NS091006-10 and 5T32NS091006-10), the Institute for Translational Medicine and Therapeutics of the Perelman School of Medicine at the University of Pennsylvania, and the Michael J. Fox Foundation (Write Now! Award). Study sponsors had no role in the data for the present study.

Acknowledgements: Protocol information for The Parkinson's Progression Markers Initiative (PPMI) Clinical - Establishing a Deeply Phenotyped PD Cohort AM 3.2. can be found on protocols.io or by following this link: ttps://dx.doi.org/10.17504/protocols.io.n92ldmw6ol5b/v2. PPMI – a public-private partnership – is funded by the Michael J. Fox Foundation for Parkinson's Research and funding partners, including 4D Pharma, Abbvie, AcureX, Allergan, Amathus Therapeutics, Aligning Science Across Parkinson's, AskBio, Avid Radiopharmaceuticals, BIAL, BioArctic, Biogen, Biohaven, BioLegend, BlueRock Therapeutics, Bristol-Myers Squibb, Calico Labs, Capsida Biotherapeutics, Celgene, Cerevel Therapeutics, Coave Therapeutics, DaCapo Brainscience, Denali, Edmond J. Safra Foundation, Eli Lilly, Gain Therapeutics, GE HealthCare, Genentech, GSK, Golub Capital, Handl Therapeutics, Insitro, Jazz Pharmaceuticals, Johnson & Johnson Innovative Medicine, Lundbeck, Merck, Meso Scale Discovery, Mission Therapeutics, Neurocrine Biosciences, Neuron23, Neuropore, Pfizer, Piramal, Prevail Therapeutics, Roche, Sanofi, Servier, Sun Pharma Advanced Research Company, Takeda, Teva, UCB, Vanqua Bio, Verily, Voyager Therapeutics, the Weston Family Foundation and Yumanity Therapeutics.

Code Availability: Code is available at https://github.com/KHefter/PPMIFallsAndInjury.

Data Availability: Data used in the preparation of this article were obtained on 2024-12-11 and 2025-01-10 from the Parkinson's Progression Markers Initiative (PPMI) database (https://www.ppmi-info.org/access-data-specimens/download-data), RRID:SCR_006431. For up-to-date information on the study, visit http://www.ppmi-info.org. This analysis used data openly available from the PPMI (Tier 1 data).

ABSTRACT

Background: Falls are an important source of morbidity in Parkinson's disease (PD). The evolution of falls and related outcomes over time remains unknown.

Objectives: To compare the risk of falls and outcomes between PD, prodromal alpha-synucleinopathy, and healthy controls (HC); estimate fall frequency and outcomes across PD progression; and characterize clinical features and outcomes across faller subgroups in PD.

Methods: We analyzed clinical features and fall-related outcomes from the Parkinson's Progression Markers Initiative across PD, prodromal alpha-synucleinopathy, and HC cohorts. We estimated the yearly rates of rare and frequent falls by time since diagnosis. We used data from unique PD participants to construct cross-sectional groups of never, rare, or frequent fallers. Clinical variables included motor, cognitive, behavioral, sleep, and autonomic measures. Outcomes included injuries and healthcare utilization. Linear and logistic regression models tested associations while adjusting for age, sex, and years since diagnosis. The Benjamini-Hochberg correction controlled for multiple comparisons.

Results: We included 3,100 participants (937 PD, 1,926 prodromal alpha-synucleinopathy, 237 HC) across 6,977 visits. PD participants had higher odds of falling than prodromal (OR=1.72, 95% CI [1.51-1.94]) and HC (OR=3.45, 95% CI [2.70-4.46]). They were also more likely to report fall-related injuries and healthcare use than prodromal (OR=1.79, 95% CI [1.49-2.14] and OR=1.87, 95% CI [1.52-2.29], respectively) and HC (OR=2.77, 95% CI [1.94-4.10] and OR=2.99, 95% CI [1.96-4.77], respectively). Falls were recorded in 15.5% of visits at diagnosis and 69.2% after 14 years. Falls increased across Neuronal Synuclein Disease-Integrated Staging System (NSD-ISS) stages. Fall-related injuries and healthcare utilization increased with disease duration and NSD-ISS stages. Among unique PD participants, frequent fallers had longer disease duration, higher NSD-ISS, and worse clinical profiles. Female PD participants were more likely to fall than males (46.1% versus 34.9%, p=0.002) despite having a milder clinical profile.

Discussion: Falls and related morbidity increase with disease duration and NSD-ISS. Risk is driven by sex and motor and non-motor factors, supporting a multifactorial model of fall susceptibility. The strong link between fall frequency and NSD-ISS supports its clinical relevance. Fall frequency may serve as a practical marker of disease progression and inform fall prevention strategies in PD.

INTRODUCTION

Falls are a common and important source of morbidity and mortality in People with Parkinson's disease (PwP). PwP fall twice as often as age-matched individuals without Parkinson's disease,[1] 60% of PwP fall at least once during their illness,[2] and 9% transition annually from having no or rare falls to having monthly falls.[3] The consequences of falls include fractures, hospital admissions, and reduced quality of life.[4] PwP have a three-fold increased risk of sustaining a hip fracture compared with non-PwP,[5] and post-fracture mortality is twice as high as that of those without Parkinson's disease (PD).[6] Consequently, a significant portion of the increased health care costs due to PD, estimated at $7.1 billion USD in 2017,[7] is likely attributable to falls, although their specific cost has not been separately quantified.

Several clinical risk factors for falls are reported. Not surprisingly, a history of a prior fall is one of the strongest and most consistent predictors of future falls in PD.[8] Motor impairment, such as the presence of freezing of gait, postural instability, and greater Hoehn & Yahr (H&Y) and Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III scores are associated with fall risk.[9] The postural instability/gait difficulty (PIGD) phenotype of PD is also associated with greater fall risk, compared to the tremor-dominant phenotype.[2] Cognitive features, including global cognitive decline and processing speed dysfunction,[10,11] as well as domain-specific inattention and executive dysfunction,[12] increase fall risk. Autonomic system risk factors, such as neurogenic orthostatic hypotension (OH), are frequent in PwP and have been associated with fall risk due to fainting.[13] Unfortunately, our knowledge of fall risk factors and outcomes currently comes from retrospective or short-duration prospective studies, which limit our understanding of their evolution as the disease progresses.

In this study, using the Parkinson's Progression Markers Initiative (PPMI) dataset, we aimed to: (1) compare the risk of falls and related outcomes among PD, prodromal alpha-synucleinopathy, and healthy controls (HC); (2) estimate fall frequency across PD duration and biological stages; and (3) characterize fall-related clinical features and outcomes across of patients prone to falling in PD. Our goal was to identify patients who are likely to fall, so that integrated strategies to prophylactically mitigate falls and injury risk could be implemented.

METHODS

Standard Protocol Approvals, Registrations, and Patient Consents

The study was approved by the internal review boards of all participating PPMI clinical sites. All participants gave written informed consent for participation in the study. Data, protocol, and materials may be requested from the PPMI at https://www.ppmi-info.org. For this cross-sectional study, we adhered to the STROBE reporting guidelines.[14]

Study design

PPMI is a multicenter, international, prospective cohort study.[15] To address our study objectives, we first assessed fall frequency and related outcomes at each study visit among participants with PD, prodromal alpha-synucleinopathy, and HC. We then created a cross-sectional analytic dataset by extracting clinical data from PD participants across visits. This dataset was designed to include adequately sized groups of unique PwP who had experienced varied fall frequencies. Each PwP was included only once in the dataset and assigned to a single group. Details on how the groups were created are provided in the description of the statistical analysis.

Participants

Briefly, PwP were required to be aged 30 years or older (at diagnosis); have a H&Y score of <3, and must have at least two of the following: resting tremor, bradykinesia, rigidity (must have either resting tremor or bradykinesia), OR either asymmetric resting tremor or asymmetric bradykinesia; and evidence of dopaminergic deficit consistent with PD based on dopamine transporter single-photon emission computed tomography (DAT SPECT) imaging. Prodromal alpha-synucleinopathy participants had hyposmia and/or REM Sleep Behavior Disorder (RBD) with mild deficits on DAT SPECT, without pathogenic genetic variants that increase the risk of developing PD. Healthy controls had no clinically significant neurological disorder, no first-degree relative with PD, and normal DAT SPECT.

Data sources for this study included: 1. Curated public data cut (v.20241211) and 2. Determination of Freezing and Falls (v.20250110). We excluded participants with known monogenic PD and those without any fall data.

Clinical variables

PPMI participants had comprehensive evaluations at annual study visits.[16] From these data, we analyzed demographic and clinical variables, including age, sex (assigned at birth), race, ethnicity, years of education, body mass index (kg/m2), disease duration (months from diagnosis), levodopa equivalent daily dose (LEDD),[17] modified Schwab and England Activities of Daily Living Scale (S&E), and Neuronal Synuclein Disease Integrated Staging System (NSD-ISS).[18] We also analyzed assessments of motor, cognitive, behavioral, sleep, and autonomic measures.[19] Motor assessments included MDS-UPDRS, H&Y stage, and PIGD scores.[20] Cognitive assessments included Montreal Cognitive Assessment (MoCA), Benton Judgment of Line Orientation (BJLO), Clock Drawing Test, Modified Boston Naming Test (MBNT), Hopkins Verbal Learning Test (HVLT), Symbol Digit Modalities Test (SDMT), and Trails Making Test (TMT). Behavioral assessments included Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease (QUIP), Geriatric Depression Scale (GDS-15), and State-Trait Anxiety Inventory (STAI). Sleep assessments included the Epworth Sleepiness Scale (ESS) and RBD Screening Questionnaire (RBDSQ). Autonomic assessments included Scales for Outcomes in Parkinson's disease – Autonomic Dysfunction (SCOPA) and orthostatic (supine to standing) change in systolic blood pressure. No data imputation was performed for missing clinical variables.

Determination of falls, injury, and healthcare utilization

We assessed falls using self-reported modified items 13 and 14 of the Unified Parkinson's Disease Rating Scale (UPDRS)– Part II,[21] introduced in PPMI in 2019 for yearly collection. Item 13 describes falls unrelated to freezing, whereas item 14 describes freezing of gait, including falls related to freezing of gait, within the last week and 12 months. We combined responses in both time frames and selected the one with higher scores. Fall frequency was defined as "none", "rare", and "frequent" based on the item responses reported in eTable 1. We assessed fall-related injury and healthcare utilization via self-reported binary questionnaires about the presence or absence of different injuries and healthcare utilization because of falls in the past year. We collected the following injuries: hip fracture, upper extremity fracture, skull fracture, other fracture, head injury, laceration requiring sutures, and other injuries. We collected data on the following care delivery settings after a fall: outpatient clinic visit, emergency department visit,

inpatient hospitalization, surgery, and institutionalization. We determined fall frequency, injury, and healthcare utilization at each yearly visit. No data was entered when fall frequency was not recorded. For visits with documented falls but missing data on injury or healthcare utilization, these outcomes were assumed not to have occurred. In all other cases, missing injury or healthcare utilization data were left blank.

Statistical analysis

All statistical analyses were conducted using R 4.5.0 (R Foundation for Statistical Computing, Vienna, Austria).

Frequency of falls and fall-related outcomes between PD, prodromal alpha-synucleinopathy, and HC

We first analyzed the number of falls, injuries, and healthcare utilization for all participants and the three cohorts across all years. We used logistic regression models with PD as the reference cohort to predict the likelihood of falls, injuries, and healthcare utilization, adjusting for age and sex. To assess the additive effect of each cohort on each outcome, we conducted Wald tests for all models. For variables with a positive Wald test (i.e., cohort membership was significant), we calculated the odds ratio (OR) for PD compared to other cohorts, and for female compared to male participants, based on model coefficients. To correct for multiple comparisons, we applied the Benjamini-Hochberg (BH) procedure to p-values associated with coefficient significance values, controlling the false discovery rate (FDR) at 0.05, which corresponded to a p-value threshold of $p<0.020$.

Next, we evaluated the effect of fall frequency on fall-related injury and health care utilization rates in PD and prodromal alpha-synucleinopathy. We created logistic models for each fall, injury, and healthcare utilization outcome, using age, sex, and cohort as covariates. We applied a BH multiple comparison correction (FDR = 0.05, $p<0.021$). ORs were calculated for PD/prodromal alpha-synucleinopathy, frequent/rare fallers, and female/male patients.

Frequency of falls and fall-related outcomes across disease duration in PD

In the total PD cohort, fall frequency was assessed at each yearly visit and categorized by the subject's disease duration, rounded to the nearest year, and NSD-ISS stage. We then calculated the proportion of visits with falls, injury, and healthcare utilization for each year of disease duration and each NSD-ISS stage. Thus, we allowed a single PwP to contribute data to multiple follow-up years whenever fall data were available.

Correlates of falling between faller groups and sex in PD

Because the fall questionnaire was introduced in 2019, participants enrolled earlier often lacked fall data in the initial years of follow-up, leading to incomplete longitudinal records. To reduce confounding from unmodeled repeated measures and improve the reliability of group classification, we constructed a cross-sectional dataset in which each participant contributed a single observation. Only participants with at least two consecutive years of fall data were included, and individuals were assigned to one of three mutually exclusive fall frequency groups: never fallers, rare fallers, or frequent fallers. Participants' first occurrence of either "rare-frequent" or "frequent-frequent" fall years were labeled as "frequent fallers", and available variables from the last observation in that time frame were taken. These individuals were then removed from the pool of participants who could be considered as either "never fallers" or "rare fallers." Then, participants' first occurrence of the combination of either "none-rare" or "rare-rare" fall years were labeled as "rare fallers," available variables from the last observation in that time frame were taken, and those participants were removed from the pool of participants who could be considered as "never fallers." Finally, participants' first occurrence of two consecutive "none" years were sampled and labeled as "never fallers," and available variables from the last observation in that time frame were taken. Based on this process, an individual subject could only be counted in one category, even if they progressed from being a never faller to a frequent faller over the subsequent study visits. Given the low counts of injury and health care utilization, participants were noted as having an injury or using health care if it was reported in either of the two consecutive years used for their sample.

We then evaluated differences between fall frequency groups and sexes. We summarized variables using counts and proportions, as well as means and standard deviations, as appropriate. For categorical and continuous variables, we used logistic models and linear regression models,

respectively, with age, sex, and years since diagnosis as covariates. For pairwise comparisons between fall frequency groups, the reference group was set to "rare fallers." To account for multiple comparisons, we used a BH correction (FDR = 0.05, p<0.017).

RESULTS

Across all cohorts, a total of 3,805 individuals were evaluated for inclusion: 1,442 with PD, 2,045 prodromal alpha-synucleinopathy, and 318 HC. Of these, 360 PD patients had monogenic PD and were excluded, and 705 participants across all groups (e.g., 505 PD, 119 prodromal alpha-synucleinopathy, and 81 HC) were excluded because fall data were missing for all study years. These exclusions resulted in a final sample of 3,100 participants (i.e., 937 with PD, 1,926 prodromal alpha-synucleinopathy, and 237 HC). 6,977 visits (e.g., 2,372 from PD, 3,848 from prodromal alpha-synucleinopathy, and 757 from HC) were analyzed. The mean ages across visits with fall data were 62.5 y (SD ± 9.36) for PD, 65.8 y (SD ± 7.0) for prodromal alpha-synucleinopathy, and 60.9 y (SD ± 11.6) for HC. The proportion of male participants was highest in the PD group (66.1%), followed by HC (61.0%) and prodromal alpha-synucleinopathy (48.8%). Falls were reported in 1,607 yearly visits. In PD, 514 visits had rare falls, and 163 visits had frequent falls (21.7% and 6.9%, respectively); in prodromal alpha-synucleinopathy, 804 visits had rare falls, and 46 visits had frequent falls (20.9% and 1.1%, respectively); and in HC, 78 visits had rare falls, and two visits had frequent falls (10.3% and 0.2%, respectively).

Comparison of risk of falls, injury, and healthcare utilization between PD, prodromal alpha-synucleinopathy, and HC

In the total sample of 3,100 participants across 6,977 visits, PwP were significantly more likely to report falling, as well as fall-related injury and healthcare utilization, compared to both prodromal alpha-synucleinopathy and HC (eTable 2). After adjusting for age and sex, PwP had 1.72 times the odds of falling compared to prodromal alpha-synucleinopathy (95% CI: 1.51, 1.94), and 3.45 times the odds compared to HC (95% CI: 2.70, 4.46). They also had 1.79 times the odds of reporting an injury from a fall compared to prodromal alpha-synucleinopathy (95% CI: 1.49, 2.14), and 2.77 times the odds compared to HC (95% CI: 1.94, 4.10). PwP had 1.87 times the odds of receiving healthcare after a fall compared to prodromal alpha-synucleinopathy (95% CI: 1.52, 2.29), and 2.99 times the odds compared to HC (95% CI: 1.96, 4.77). We next

investigated whether the observed differences in injury and healthcare utilization between cohorts could be explained by differences in fall frequency rather than by cohort membership itself (i.e., PD versus prodromal alpha-synucleinopathy). Cohort membership was no longer a significant predictor of injury or healthcare utilization (eTable 3), whereas fall frequency remained a robust and consistent predictor (eTable 4).

Falls, injury, and healthcare utilization in PD across years since diagnosis and NSD-ISS stages

In 937 participants with PD across 2,372 visits, fall frequency increased with disease progression and NSD-ISS stages. At 0, 7, and 14 years of years since diagnosis, falls were reported during 15.5%, 36.3%, and 69.2% of visits, respectively (Figure 1A). At those same time points, rare falls were reported in 14.0%, 25.3%, and 38.5% of visits, while frequent falls were reported in 1.4%, 11.0%, and 30.8% of visits, respectively. Injury and healthcare utilization also increased with years since diagnosis (Figure 1B). At 0, 7, and 14 years of years since diagnosis, fall-related injuries were reported in 4.3%, 14.3%, and 46.2% of visits, and fall-related healthcare utilization was reported in 2.5%, 9.9%, and 30.8% of visits, respectively. Among visits in which a fall was reported, the proportion with a fall-related injury increased with years since diagnosis, reaching 27.9%, 39.4%, and 66.7% at years 0, 7, and 14, respectively.

NSD-ISS data were available for 92.1% of visits (eTable 5). Falls were not reported in NSD-ISS stage 2A, and only rare falls were observed in stage 2B. In contrast, fall frequency increased progressively across higher disability NSD-ISS stages, with frequent falls reported in 2.1% of visits at stage 3, 12.8% at stage 4, 47.0% at stage 5, and 77.8% at stage 6 (Figure 2A). Higher NSD-ISS stages were also associated with increased rates of injury and healthcare utilization (Figure 2B). In NSD-ISS stages 3, 4, 5, and 6, injuries were reported in 7.1%, 18.0%, 44.6%, and 77.8% of visits, and healthcare utilization in 5.4%, 14.8%, 34.9%, and 66.7% of visits, respectively.

Cross-sectional differences between never, rare, and frequent fallers in unique participants with PD

To determine risk factors and differences in outcomes in unique participants, we classified 371, 178, and 56 unique participants as never fallers, rare fallers, and frequent fallers, respectively (eFigure 1). After adjusting for age and years since diagnosis, male sex was more common in both never fallers and frequent fallers compared to rare fallers (Table 1). Female PwP were significantly more likely than males to report any fall occurrence (46.1% versus 34.9%) after adjusting for age and years since diagnosis (eTable 6). This difference was driven by rare (39.7% versus 24.2%), but not frequent falls (6.4% versus 10.7%). Years since diagnosis were longest among frequent fallers and shortest among never fallers. NSD-ISS stage followed a similar pattern: frequent fallers had the highest average disease stage and never fallers the lowest. Logistic regression analysis confirmed that fall frequency was a significant correlate of NSD-ISS stage, with never fallers being more likely to be in early stages and frequent fallers more likely to be in late stages, both compared to rare fallers. S&E score was significantly lower among frequent fallers, indicating greater functional impairment, while differences in LEDD were not statistically significant.

Motor and non-motor differences between never, rare, and frequent fallers

Frequent fallers exhibited significantly worse motor and non-motor profiles compared to rare and never fallers (Table 2). Motor severity, including higher H&Y stages and PIGD scores in both ON and OFF states, was greatest in frequent fallers (eFigure 2). Total MDS-UPDRS scores and Part II and III sub scores were also elevated in this group, while never fallers showed milder impairment. Differences between never and rare fallers were limited, reaching significance primarily for PIGD scores. MDS-UPDRS Part IV scores were higher in frequent fallers compared to rare fallers, but did not differ significantly between never and rare fallers.

Non-motor symptoms followed a similar gradient (eFigure 3). Frequent fallers had higher MDS-UPDRS Part I scores, greater depressive and anxiety symptoms, and worse autonomic dysfunction, particularly in gastrointestinal, cardiovascular, urinary, and thermoregulatory domains. Cognitive performance also differed across groups. Frequent fallers had lower MoCA scores than rare fallers, and worse performance on measures of processing speed (SDMT), visuospatial judgment (BJLO), and executive function (TMT-B). Several cognitive domains

showed no significant differences across groups. Although OH was more common in frequent fallers, this association was not statistically significant after adjusting for confounders.

Female PwP had milder PD symptoms, scoring five points lower on the total MDS-UPDRS ON exam, and specifically 1.5 points lower on MDS-UPDRS Part II, than their male counterparts (eTable 6). Notably, MDS-UPDRS Part III, PIGD, and H&Y were not significantly different between sexes on either ON or OFF states. Cognitively, female PwP outperformed males on several domains, including verbal learning and memory (e.g., HVLT), verbal fluency (e.g., LFLT), processing speed (e.g., SDMT), and cognitive flexibility and visual attention (e.g., TMT Parts A and B). In contrast, male PwP performed better on visuospatial judgment (e.g., BJLO). Finally, female PwP were less likely to have sleep disturbances, with a lower percentage of RBDSQ ≥ 5 rates and a lower average ESS.

Fall-related outcome differences between rare and frequent fallers
Frequent fallers were significantly more likely than rare fallers to report any fall-related injury in the previous year (66.1% versus 39.9%), including head injuries (33.9% versus 11.8%), lacerations (25% versus 6.7%), and multiple injuries (33.9% versus 8.4%; Table 3). They also reported higher rates of emergency department visits (50% versus 20.2%) due to fall-related injuries (eFigure 4). Female PwP were more likely to report any fracture (10.3% versus 4.24%), particularly upper extremity fractures (5.4% versus 1.8%) than their male counterparts (eFigure 5). Differences in hip fractures between female and male PwP (3.4% versus 0.8%) did not reach statistical significance (eTable 6).

DISCUSSION
In this large, multicohort study of individuals across the PD spectrum, we found that falls and fall-related morbidity were significantly more common in PwP compared to those with prodromal alpha-synucleinopathy or HC. Fall-related injuries and healthcare utilization were also markedly more frequent in PD, primarily due to increased fall frequency rather than PD diagnosis alone. These outcomes increased in parallel with years since diagnosis and NSD-ISS stage. In cross-sectional analyses of unique PwP, frequent fallers had greater disability, more severe motor, cognitive, and non-motor symptoms compared to rare or never fallers. Notably,

female sex emerged as a strong and independent predictor of fall risk and related morbidity, even in the context of a milder overall clinical phenotype.

In our cohort, falls occurred in over one in four visits among PwP and increased with both years since diagnosis and advancing disability, as indicated by NSD-ISS stage 4 or higher. By 14 years post-diagnosis, seven out of ten visits reported a fall, and nearly one-third involved frequent falls. A similar trend was observed for fall-related injuries and healthcare utilization, suggesting that PD progression contributes not only to fall risk but also to their severity and consequences. Notably, approximately 15% of PwP had already experienced a fall in the past year at the time of diagnosis, nearly all of which were classified as rare. Although the injury rate at diagnosis was relatively low, with approximately one injury per 20 falls, this finding supports the need for fall screening from the time of diagnosis, as listed in the American Academy of Neurology's universal neurology quality measurement set.[22] Early screening can inform both primary prevention strategies, such as physical therapy and home safety evaluations, and secondary prevention efforts, including the use of assistive devices and bone health management.

Our findings should be interpreted in the context of the existing literature on falls in Parkinson's disease. In 22 prior studies, an average of 60.5% of individuals with PD reported at least one fall.[23] Among community-dwelling individuals without dementia, similar to our study population, yearly fall rates have ranged from 21% to 65% when followed for up to 12 months.[24–31] Longitudinal studies have also described high rates of frequent falls. For example, in the Norwegian ParkWest study,[32] 46% of participants with newly diagnosed PD experienced frequent falls by a median follow-up time of six years. These rates are higher than those observed in our study, which may reflect length-of-time bias. Individuals with slower disease progression are more likely to remain in long-term follow-up, and thus overrepresented in our sample, potentially leading to an underestimation of the true frequency of falls. The relationship between fall frequency and NSD-ISS stage further supports the validity of this recently proposed staging system. Although falls are not incorporated into the NSD-ISS criteria, fall frequency increased consistently across higher stages. This aligns the transition from NSD-ISS stage 3 to 4 as an inflexion point linked to a meaningful, patient-centered outcome and reinforces the framework of increasing levels of disability at increasing stages.[33] Overall, our study extends the literature by

providing prospective estimates of fall frequency across a wide range of years since diagnosis, identifying associated clinical and biological features, and demonstrating the utility of NSD-ISS staging in stratifying fall-related vulnerability in PD.

In our cross-sectional analyses of unique PwP, we observed meaningful differences across fall frequency groups. Frequent fallers had longer years since diagnosis, higher NSD-ISS stages, greater functional impairment, and more severe motor and non-motor symptoms compared to rare or never fallers. Frequent fallers had higher H&Y stages, PIGD scores, and MDS-UPDRS total and subscale scores. Despite these marked group differences in motor variables, LEDD did not significantly differ between groups, suggesting that dopaminergic medication dose may not influence fall risk. Additionally, global and domain-specific cognitive measures, including processing speed, executive function, and visuospatial perception, showed expected decrements in frequent fallers. However, the lack of significant differences across several other cognitive domains highlights the selective nature of cognitive vulnerability in PwP, as reported by others.[11] Finally, although the rates of OH showed an increasing trend with increasing fall frequency, this effect was driven by confounders (e.g., age and years since diagnosis). Contrarily, SCOPA cardiovascular, which captures patient-reported symptoms related to OH, was significantly worse in frequent fallers. This mismatch between objective and subjective OH symptoms and fall risk may be explained by differences in immediate versus delayed or symptomatic versus asymptomatic OH,[34] which may contribute differently to fall risk.

Sex remained a consistent predictor of fall risk and fall-related outcomes across all analyses. Female PwP, despite having lower LEDD requirements, milder motor symptoms, and superior cognitive performance on several domains, were significantly more likely to report falls, injuries, and fall-related healthcare use compared to males, even after adjusting for age, years since diagnosis, and fall frequency. Among female PwP, the increased risk was most pronounced for rare falls and upper extremity fractures; hip fractures did not achieve statistical significance due to low absolute frequencies. Active research is ongoing to test the efficacy of osteoporosis treatment in fracture prevention for PwP,[35] a condition that disproportionately affects women.[36] Several factors may contribute to these observed sex differences. From a biomechanical perspective, females typically have a lower center of mass due to a wider pelvis and lower-body

muscle distribution, which may improve static stability but hinder recovery after imbalance.[37] Males, with a higher center of mass from upper-body muscle mass, may be more prone to imbalance yet better able to make rapid corrective movements.[37] Specifically in PwP, female PwP have consistently been shown to have a higher risk of falling, independent of age,[38,39] despite having less rigidity and fewer axial symptoms than males.[40] Additional female-associated fall risk factors may include urinary incontinence,[41] traditional gendered expectations (e.g., domestic tasks such as cooking and cleaning),[42] a lower socioeconomic status,[43] or a greater willingness to report falls and seek healthcare than their male counterparts.[44] These findings highlight a potential disconnect between traditional clinical markers of disease severity and real-world functional vulnerability in women with PD. More work is needed to understand the social and environmental factors around falls, and to craft interventions that promote safe autonomy for PwP.

Our study has several limitations. As noted earlier, differential withdrawal of participants from PPMI who were experiencing increasing disability, including falls, may contribute to underestimates of the rate of falling in more advanced PD. Second, we did not evaluate the effect of socioeconomic status, comorbidities, or polypharmacy in our analysis, factors known to increase fall risk. Our fall definitions rely on self-report and are derived from a yearly questionnaire and not from a fall diary (i.e., the gold standard), which raises concerns about underreporting due to participants' forgetfulness or social desirability bias (i.e., underreporting to appear healthier). We aimed to mitigate this limitation by adopting a stringent sampling method requiring consecutive fall reporting years for our cross-sectional analysis. Finally, although our analysis spans over 15 years since diagnosis, the mean years since diagnosis for unique participants was 5 years. This is in part due to the nature of the fall questionnaire, which was introduced several years after the inception of PPMI. Participants enrolled earlier generally had more years since diagnosis, whereas those enrolled later had fewer years since diagnosis. We alleviated the potential confounding effect by adjusting our analyses for years since diagnosis.

CONCLUSION

Our findings highlight the high burden of falls and fall-related outcomes in PD, driven by disease progression and amplified by sex-specific vulnerabilities. Fall risk was associated with motor,

cognitive, behavioral, and autonomic dysfunction, supporting a multifactorial model of fall susceptibility. The strong association between fall frequency and NSD-ISS stage further validates this staging system as a meaningful clinical tool. These results highlight the need for early fall screening, personalized prevention strategies, and increased attention to sex-specific risks to reduce fall-related morbidity in PD. Fall frequency may serve as a simple and informative marker of disease progression in PD.

REFERENCES

1. Camicioli R, Morris ME, Pieruccini☐Faria F, et al. Prevention of Falls in Parkinson's Disease: Guidelines and Gaps. Mov Disord Clin Pract. 2023;10:1459–1469.

2. Pelicioni PHS, Menant JC, Latt MD, Lord SR. Falls in Parkinson's Disease Subtypes: Risk Factors, Locations and Circumstances. Int J Environ Res Public Health. 2019;16:2216.

3. Parashos SA, Bloem BR, Browner NM, et al. What predicts falls in Parkinson disease? Neurol Clin Pract. 2018;8:214–222.

4. Grimbergen YAM, Schrag A, Mazibrada G, Borm GF, Bloem BR. Impact of Falls and Fear of Falling on Health-Related Quality of Life in Patients with Parkinson's Disease. J Park Dis. 2013;3:409–413.

5. Hosseinzadeh A, Khalili M, Sedighi B, Iranpour S, Haghdoost AA. Parkinson's disease and risk of hip fracture: systematic review and meta-analysis. Acta Neurol Belg. 2018;118:201–210.

6. Nam JS, Kim YW, Shin J, Chang JS, Yoon SY. Hip Fracture in Patients with Parkinson's Disease and Related Mortality: A Population-Based Study in Korea. Gerontology. 2021;67:544–553.

7. Yang W, Hamilton JL, Kopil C, et al. Current and projected future economic burden of Parkinson's disease in the U.S. npj Park Dis. 2020;6:15.

8. Pickering RM, Grimbergen YAM, Rigney U, et al. A meta☐analysis of six prospective studies of falling in Parkinson's disease. Mov Disord. 2007;22:1892–1900.

9. Wood BH. Incidence and prediction of falls in Parkinson's disease: a prospective multidisciplinary study. J Neurol Neurosurg Psychiatry. 2002;72:721–725.

10. Lindholm B, Brogårdh C, Odin P, Hagell P. Longitudinal prediction of falls and near falls frequencies in Parkinson's disease: a prospective cohort study. J Neurol. 2021;268:997–1005.

11. Anis S, Zimmerman E, Jansen AE, et al. Cognitive measures predict falls in Parkinson's disease: Insights from the CYCLE-II cohort. Parkinsonism Relat Disord. 2025;133:107328.

12. Montero☐Odasso M, Speechley M. Falls in Cognitively Impaired Older Adults: Implications for Risk Assessment And Prevention. J Am Geriatr Soc. 2018;66:367–375.

13. Fanciulli A, Campese N, Goebel G, et al. Association of transient orthostatic hypotension with falls and syncope in patients with Parkinson disease. Neurology. 2020;95.

14. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies. Ann Intern Med. 2007;147:573–577.

15. Marek K, Jennings D, Lasch S, et al. The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol. 2011;95:629–635.

16. Marek K, Chowdhury S, Siderowf A, et al. The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort. Ann Clin Transl Neurol. 2018;5:1460–1477.

17. Jost ST, Kaldenbach M, Antonini A, et al. Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals. Mov Disord. 2023;38:1236–1252.

18. Simuni T, Chahine LM, Poston K, et al. A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research. Lancet Neurol. 2024;23:178–190.

19. Brumm MC, Siderowf A, Simuni T, et al. Parkinson's Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson's Disease Progression. J Park Dis. 2023;13:899–916.

20. Stebbins GT, Goetz CG, Burn DJ, Jankovic J, Khoo TK, Tilley BC. How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: Comparison with the unified Parkinson's disease rating scale. Mov Disord. 2013;28:668–670.

21. Fahn S, Elton R, Committee M of the UD. Members of the UPDRS Development Committee. In: Fahn S, Marsden CD, Calne DB, Goldstein M, editors. Recent Dev Park Dis Vol 2. Florham Park, NJ: Macmillan Health Care Information; 1987. p. 153–163.

22. Martello J, Buchhalter J, Das RR, Dubinsky R, Lee E, Anderson W. Quality improvement in neurology. Neurology. 2019;92:418–426.

23. Allen NE, Schwarzel AK, Canning CG. Recurrent Falls in Parkinson's Disease: A Systematic Review. Parkinsons Dis. 2013;2013:1–16.

24. Allcock LM, Rowan EN, Steen IN, Wesnes K, Kenny RA, Burn DJ. Impaired attention

predicts falling in Parkinson's disease. Parkinsonism Relat Disord. 2009;15:110–115.

25. Bloem BR, Grimbergen YAM, Cramer M, Willemsen M, Zwinderman AH. Prospective assessment of falls in Parkinson's disease. J Neurol. 2001;248:950–958.

26. Cole MH, Silburn PA, Wood JM, Worringham CJ, Kerr GK. Falls in Parkinson's disease: Kinematic evidence for impaired head and trunk control. Mov Disord. 2010;25:2369–2378.

27. Foreman KB, Addison O, Kim HS, Dibble LE. Testing balance and fall risk in persons with Parkinson disease, an argument for ecologically valid testing. Parkinsonism Relat Disord. 2011;17:166–171.

28. Hayashi R, Aizawa J, Nagase H, Ohara S. Lateral inclination of the trunk and falling frequency in Parkinson's disease patients. Electromyogr Clin Neurophysiol. 2010;50:195–202.

29. Kerr GK, Worringham CJ, Cole MH, Lacherez PF, Wood JM, Silburn PA. Predictors of future falls in Parkinson disease. Neurology. 2010;75:116–124.

30. Latt MD, Lord SR, Morris JGL, Fung VSC. Clinical and physiological assessments for elucidating falls risk in Parkinson's disease. Mov Disord. 2009;24:1280–1289.

31. Mak MKY, Pang MYC. Parkinsonian single fallers versus recurrent fallers: different fall characteristics and clinical features. J Neurol. 2010;257:1543–1551.

32. Gonzalez MC, Dalen I, Maple-Grødem J, Tysnes O-B, Alves G. Parkinson's disease clinical milestones and mortality. NPJ Park Dis. 2022;8:58.

33. Dam T, Pagano G, Brumm MC, et al. Neuronal alpha-Synuclein Disease integrated staging system performance in PPMI, PASADENA, and SPARK baseline cohorts. npj Park Dis. 2024;10:178.

34. Palma J-A, Kaufmann H. Orthostatic Hypotension in Parkinson Disease. Clin Geriatr Med. 2020;36:53–67.

35. Tanner CM, Cummings SR, Schwarzschild MA, et al. The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism. npj Park Dis. 2021;7:16.

36. Alswat KA. Gender Disparities in Osteoporosis. J Clin Med Res. 2017;9:382–387.

37. Khobkhun F, Thanakamchokchai J. Biological sex-related differences in whole-body coordination during standing turns in healthy young adults. Sci Rep. 2023;13:22112.

38. Cerri S, Mus L, Blandini F. Parkinson's Disease in Women and Men: What's the Difference? J Park Dis. 2019;9:501–515.

39. Chou KL, Elm JJ, Wielinski CL, et al. Factors associated with falling in early, treated Parkinson's disease: The NET-PD LS1 cohort. J Neurol Sci. 2017;377:137–143.

40. Miller IN, Cronin□Golomb A. Gender differences in Parkinson's disease: Clinical characteristics and cognition. Mov Disord. 2010;25:2695–2703.

41. Gale CR, Cooper C, Aihie Sayer A. Prevalence and risk factors for falls in older men and women: The English Longitudinal Study of Ageing. Age Ageing. 2016;45:789–794.

42. Duckham RL, Procter-Gray E, Hannan MT, Leveille SG, Lipsitz LA, Li W. Sex differences in circumstances and consequences of outdoor and indoor falls in older adults in the MOBILIZE Boston cohort study. BMC Geriatr. 2013;13:133.

43. Syddall H, Evandrou M, Cooper C, Aihie Sayer A. Social Inequalities in Grip Strength, Physical Function, and Falls Among Community Dwelling Older Men and Women. J Aging Health. 2009;21:913–939.

44. Stevens JA, Ballesteros MF, Mack KA, Rudd RA, DeCaro E, Adler G. Gender Differences in Seeking Care for Falls in the Aged Medicare Population. Am J Prev Med. 2012;43:59–62.

Authors' disclosures:

JAV: is an employee of the University of Pennsylvania and received funding support from the National Institutes of Health (1T32NS091006□10), the Institute for Translational Medicine and Therapeutics of the Perelman School of Medicine at the University of Pennsylvania, and the Michael J. Fox Foundation; honoraria from the International Parkinson and Movement Disorder Society; and consultancy fees from the University City Science Center.

KH: is a graduate student at the University of Pennsylvania and received funding from the National Institutes of Health (5T32NS091006-10).

DEL: is an employee of the University of Iowa.

MTD: is an employee of the University of Pennsylvania and received funding support from the National Institutes of Health (F30-AG074524).

AE: is an employee of the University of Pennsylvania and received funding support from the National Institutes of Health and The Patient-Centered Outcomes Research Institute.

BL: is an employee of the University of Pennsylvania and received funding support from NINDS (DP1-NS-122038-01), The Small Lake Foundation, Jonathan and Bonnie Rothberg, Neil and Barbara Smit.

DSB: is a faculty member at the University of Pennsylvania.

AS: is a faculty member at the University of Pennsylvania; consultancy fees in the past year from Acadia, Eli Lilly and Co, Neurocrine, Theravance, Cerevance, Spark/Roche, Boerhinger-Ingelheim, Wave Life Sciences, Inhibikase, Prevail, Mitzubishi and Alertity Therapeutics. He has served on DSMBs for the Huntington Study Group and The Healey ALS Consortium (Massachusetts General Hospital). He has received grant funding from the Michael J. Fox Foundation, NIA and NINDS.

Authors' roles:

JAV: Design, execution, analysis, writing, and editing of the final version of the manuscript.

KH: Design, execution, analysis, writing, and editing of the final version of the manuscript.

DEL: Editing of the final version of the manuscript.

MTD: Editing of the final version of the manuscript

AE: Analysis and editing of the final version of the manuscript.

BL: Editing of the final version of the manuscript

DSB: Analysis and editing of the final version of the manuscript

AS: Design, execution, analysis, and editing of the final version of the manuscript.

Table 1: Demographic Differences Between Never, Rare, and Frequent Fallers in the Cross-Sectional PD Cohort.

	Never Fallers (n = 371)	Rare Fallers (n = 178)	Frequent Fallers (n = 56)	p(Never ≠Rare)	p(Rare ≠Frequent
Sex: Male	261 (70.4%) *	97 (55.5%)	43 (76.8%) *	<0.001	0.01
Age (y)	62.5 (9.4) *	62.9 (9.8)	63.5 (8.7)	0.004	0.040
Years since diagnosis	3.1 (3.0) *	6.5 (4.5)	10.1 (3.6) *	<m.p.	<0.001
Race: White	344 (93.5%)	167 (95.4%)	54 (96.4%)	0.71	0.88
Ethnicity: Not Hispanic or Latino	354 (96.6%) *	166 (92.3%)	55 (98.2%)	0.006	0.44
Education years	16 (2.8)	16 (2.9)	16.1 (2.4)	0.53	0.84
BMI	27.2 (25.3)	25.3 (4.1)	26.6 (4.4)	0.24	0.46
LEDD (mg)	294 (384)	587 (572)	829 (524)	0.075	0.56
S&E	92.5 (7)	86.8 (11.5)	70.3 (17.3) *	0.029	<m.p.
NSD-ISS	321	153	49		
≤ Stage 3	264 (82.2%) *	90 (58.8%)	10 (20.4%) *	0.002	0.002
> Stage 3	57 (17.8%) *	63 (41.2%)	39 (79.6%) *	0.002	0.002
2a	1 (0.3%)	0	0		
2b	57 (17.8%)	13 (8.5%)	0		
3	206 (64.2%)	77 (50.3%)	10 (20.4%)		
4	54 (16.8%)	58 (37.9%)	27 (55.1%)		
5	3 (0.9%)	5 (3.3%)	11 (22.4%)		
6	0	0	1 (2.0%)		
Not NSD-ISS	22	13	7		

BMI, Body Mass Index; ED, Emergency Department; LEDD, Levodopa Equivalent Daily Dose; NSD-ISS, Neuronal Synuclein Disease-Integrated Staging System; S&E, Modified Schwab and England Activities of Daily Living Scale. Values are *n* or mean (with corresponding % or SD), as appropriate, *: statistically significant from rare, p<0.017 (BH threshold for FDR 0.05). m.p. = machine precision.

Table 2: Motor and Non-motor Differences Between Never, Rare, and Frequent Fallers in the Cross-Sectional PD Cohort.

	Never Fallers (n = 371)	Rare Fallers (n = 178)	Frequent Fallers (n = 56)	p(Never ≠Rare)	p(Rare ≠Frequent)
Motor Variables					
H&Y	1.8 (0.5)	2.0 (0.6)	2.6 (1.1) *	0.35	<0.001
H&Y ON	1.8 (0.5)	2.0 (0.5)	2.8 (0.9) *	0.13	<0.001
PIGD	0.3 (0.3) *	0.6 (0.5)	1.3 (0.8) *	<0.001	<m.p.
PIGD ON	0.3 (0.2) *	0.5 (0.4)	1.3 (0.8) *	<0.001	<m.p.
MDS-UPDRS	40.0 (17.5) *	53.3 (20.9)	76.1 (22) *	<0.001	<0.001
MDS-UPDRS ON	36.1 (16.1) *	45.9 (19.4)	69.3 (22) *	<0.001	<0.001.
Part 1	6.55 (4.78) *	9.26 (5.3)	15.0 (6.8) *	<0.001	<0.001
Part 2	7.18 (5.33) *	10.6 (6.3)	20.2 (8.2) *	<0.001	<m.p.
Part 3	26.3 (11.6) *	34.5 (15.2)	43.1 (13.5)	0.001	0.12
Part 3 ON	22.4 (11.0) *	26.5 (13.3)	35.8 (12.9) *	0.015	<0.001
Part 4	1.37 (2.6)	2.89 (3.6)	5.11 (4.7) *	0.24	0.007
Cognitive Variables					
MoCA	27.3 (2.4)	27.0 (3.1)	25.4 (4.2) *	0.95	0.01
BJLO	12.6 (2.4) *	11.8 (3.0)	11.8 (2.7)	0.001	0.32
Clock Drawing Test	6.2 (1.3)	6 (1.4)	5.4 (2)	0.94	0.19
LFLT	44.1 (13.8)	43.2 (14.7)	36.2 (16.1)	0.95	0.04
MBNT	56.2 (6.8)	56 (6.6)	56.8 (3.6)	0.86	0.50
HVLT: Discrimination	10.0 (2.1)	9.49 (3.0)	9.55 (2.1)	0.06	0.50
HVLT: Immediate Recall	22.9 (5.7)	22.2 (6.7)	20.5 (5.5)	0.37	0.65
HVLT: Retention	0.83 (0.3)	0.80 (0.3)	0.75 (0.3)	0.60	0.92
HVLT: False Positive	0.93 (1.1)	0.97 (1.3)	1.08 (1.2)	0.92	0.92
HVLT: Delayed Recall	7.97 (3.1)	7.55 (3.3)	6.67 (3.5)	0.33	0.64
HVLT: Recognition	11.1 (1.4)	10.7 (2.3)	10.8 (1.45)	0.028	0.52
LNST	10.8 (3)	9.80 (3.1)	8.44 (2.6)	0.08	0.16
SDMT	42.9 (10.4) *	38.4 (12.9)	30.8 (10.9)	0.01	0.02
TMT - Part A	39.0 (20.1)	46.4 (26.2)	60.2 (32.6)	0.12	0.06
TMT - Part B	90.2 (55.2)	116 (75.6)	170 (84.8) *	0.036	0.002
Behavioral Variables					
QUIP	0.2 (0.6)	0.4 (0.8)	0.518 (0.8)	0.076	0.44
GDS-15	1.88 (2.02) *	2.70 (2.6)	4.77 (3.5) *	<0.001	<0.001
STAI	59.8 (16.1) *	64.8 (18.5)	74.4 (21.7) *	0.005	<0.001
Sleep Variables					
ESS	5.70 (3.7)	6.61 (4.5)	9.09 (4.8)	0.19	0.018
RBDSQ ≥ 5	137 (37.0%)	83 (46.6%)	37 (66.0%)	0.22	0.17
Autonomic Variables					
SCOPA	11.0 (6.9)	13.8 (6.9)	19.1 (7.9) *	0.018	<0.001
OH	55 (14.9%)	35 (20.2%)	14 (27.4%)	0.75	0.96

H&Y, Hoehn and Yahr; PIGD, Postural Instability and Gait Disorder; MDS-UPDRS, Movement Disorder Society Unified Parkinson's Disease Rating Scale; MoCA, Montreal Cognitive Assessment; LFLT, Lexical Fluency Letter Test; MBNT, Modified Boston Naming Test, BJLO, Benton Judgment of Line Orientation; HVLT, Hopkins Verbal Learning Test; LNST, Letter Number Sequencing Test; SDMT, Symbol Digit Modalities Test; TMT, Trail Making Test; QUIP, Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease; GDS-15, Geriatric Depression Scale; STAI, State-Trait Anxiety Inventory; ESS, Epworth Sleepiness Scale; RBDSQ, REM Sleep Behavior Disorder Screening Questionnaire (values $\geq$ 5 are considered positive for RBD); SCOPA, Scales for Outcomes in Parkinson's Disease – Autonomic; OH, orthostatic hypotension. ON denotes the ON medication state. Values are n or mean (with corresponding % or SD), as appropriate, *: statistically significant from rare, $p<0.017$ (BH threshold for FDR 0.05). m.p. = machine precision.

Table 3: Outcome Differences Between Rare and Frequent Fallers in the Cross-Sectional PD Cohort.

	Rare Fallers (n = 178)	*Frequent Fallers (n = 56)*	*p(Rare ≠Frequent)*
Injury			
Any Injury	71 (39.9%)	37 (66.1%)	0.011 *
Any Fracture	24 (13.5%)	14 (25.0%)	0.24
Hip Fracture	7 (3.9%)	3 (5.4%)	0.87
Upper Extremity Fracture	10 (5.6%)	8 (14.3%)	0.072
Skull Fracture	2 (1.1%)	0 (0%)	1.0
Other Fracture	11 (6.2%)	7 (12.5%)	0.36
Head Injury	21 (11.8%)	19 (33.9%)	0.014 *
Laceration	12 (6.7%)	14 (25.0%)	0.017 *
Other Injury	34 (19.1%)	21 (37.5%)	0.005 *
Multiple Injuries	15 (8.4%)	19 (33.9%)	<0.001 *
Healthcare Utilization			
Any Healthcare Use	55 (30.9%)	34 (60.7%)	0.021
Outpatient Visit	32 (18.0%)	24 (42.9%)	0.031
ED Visit	36 (20.2%)	28 (50.0%)	0.005 *
Hospitalization	11 (6.2%)	9 (16.1%)	0.31
Surgery	6 (3.4%)	7 (12.5%)	0.093
Institutionalization	2 (1.1%)	0 (0%)	1.0

BMI, Body Mass Index; ED, Emergency Department; LEDD, Levodopa Equivalent Daily Dose; S&E, Modified Schwab and England Activities of Daily Living Scale. Values are *n* or mean (with corresponding % or SD), as appropriate, *: statistically significant from rare, p<0.017 (BH threshold for FDR 0.05). m.p. = machine precision.

Figure 1: Fall Frequency and Outcomes across Years Since Diagnosis in PD

In 937 patients with PD across 2372 yearly visits, the percentage of visits with (A) rare or frequent yearly falls and (B) fall-related injury and healthcare utilization is displayed across years since diagnosis.

Figure 2: Fall Frequency and Outcomes across NSD-ISS in PD

Of the 2372 visits, 2185 had NSD-ISS data. A total of 150 visits were of participants labeled not NSD-ISS (i.e., Parkinsonism not from biologically defined neuronal synuclein disease), resulting in 2035 visits with NSD-ISS. The percentage of visits with (A) rare or frequent yearly falls and (B) fall-related injury and healthcare utilization is displayed across NSD-ISS stages. NSD-ISS, Neuronal Synuclein Disease-Integrated Staging System.

A Fall Frequency by Years Since Diagnosis

A

Fall Frequency Across NSD-ISS Stage

B

Injury and Healthcare Utilization Across NSD-ISS Stage